Scientific work

Prof. Dr. Aysun Soysal

254 publications. The source of the information is stated next to each publication.

Back to profile

  1. Significance of Phrenic Nerve Conduction Study in the Electrodiagnosis of Guillain Barré Syndrome

    Journal of the Peripheral Nervous System, 2026

    DOI 10.1111/jns.70131 PMID 42227702 Open-access full textSource: ORCID

  2. CD8+CD20+ Cytotoxic T Lymphocytes Exhibit Augmented Degranulation and Pro-inflammatory Potential in Multiple Sclerosis

    Biorxiv, 2026

    DOI 10.64898/2026.01.29.702512 Open-access full textSource: ORCID

  3. Causal effects of multiple sclerosis therapies in left-truncated registry data

    Multiple Sclerosis Journal, 2026

    DOI 10.1177/13524585261459943 PMID 42479470 Open-access full textSource: ORCID

  4. Differential Associations Between Left Atrial Volume Parameters and Ischemic Stroke Subtypes

    Haseki Tip Bulteni, 2026

    DOI 10.4274/haseki.galenos.2026.70299 Open-access full textSource: ORCID

  5. Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

    Journal of Neurology, 2026

    DOI 10.1007/s00415-026-13632-4 PMID 41634506 3 citations (Europe PMC) Open-access full textSource: ORCID

  6. Evaluation of Seropositivity Developed Against Specific Antigens of Helicobacter pylori in Neurodegenerative Diseases

    Noropsikiyatri Arsivi, 2026

    DOI 10.29399/npa.29038 PMID 41613025 Open-access full textSource: ORCID

  7. Hyperintense acute reperfusion marker (HARM) and thrombus analysis in acute ischemic stroke

    Frontiers in Neurology, 2026

    DOI 10.3389/fneur.2026.1723099 PMID 41940303 Open-access full textSource: ORCID

  8. Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

    Neurology, 2026

    DOI 10.1212/wnl.0000000000214707 PMID 41785437 Source: ORCID

  9. Predicting disease progression in multiple sclerosis with clinically accessible information and technology

    Journal of Neurology, 2026

    DOI 10.1007/s00415-026-13802-4 PMID 42002655 2 citations (Europe PMC) Open-access full textSource: ORCID

  10. Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

    CNS Drugs, 2026

    DOI 10.1007/s40263-026-01287-8 PMID 41935174 1 citation (Europe PMC) Open-access full textSource: ORCID

  11. Reduced vagal reserve in benign paroxysmal positional vertigo: preliminary results of a case-control HRV study

    European Archives of Oto Rhino Laryngology, 2026

    DOI 10.1007/s00405-026-10479-3 PMID 42507201 Source: ORCID

  12. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

    Medrxiv, 2026

    DOI 10.64898/2026.03.09.26347918 Open-access full textSource: ORCID

  13. Sensory neuronopathy: evaluation of clinical and electrophysiological features, etiology, and treatment responses

    Neuroscience Applied, 2026

    DOI 10.1016/j.nsa.2025.105726 Open-access full textSource: OpenAlex

  14. Geomagnetic Disturbance and Ultraviolet Exposures Influence Multiple Sclerosis Onset Timing

    Document Server@UHasselt (UHasselt), 2026

    Open-access full textSource: OpenAlex

  15. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

    Brain, 2026

    DOI 10.1093/brain/awag252 PMID 42496160 Open-access full textSource: OpenAlex

  16. How patients with neuromyelitis optica spectrum disease accumulate disability

    Multiple Sclerosis Journal, 2026

    DOI 10.1177/13524585261489039 PMID 42847346 Open-access full textSource: OpenAlex

  17. Disease-modifying therapies in managing disability worsening in adult relapsing multiple sclerosis: a population-based longitudinal study using the MSBase registry

    BMC Medicine, 2026

    DOI 10.1186/s12916-026-05365-y Open-access full textSource: OpenAlex

  18. Antibodies against SARS-CoV-2 in cerebrospinal fluid: Clinical features and laboratory findings of hospitalized patients with neurologic symptoms in the pandemic era,SARS-CoV-2 elleni antitestek az agygerincvelői folyadékban: neurológiai tünetekkel kórházba került betegek klinikai jellemzői és laboratóriumi leletei a világjárvány idején

    Ideggyogyaszati Szemle, 2025

    DOI 10.18071/isz.77.0136 PMID 40163003 Source: ORCID

  19. CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders

    Journal of Immunology, 2025

    DOI 10.1093/jimmun/vkaf205 PMID 40849886 Open-access full textSource: ORCID

  20. CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders

    Biorxiv, 2025

    DOI 10.1101/2025.01.09.632131 Open-access full textSource: ORCID

  21. Clinical Characteristics and Prognostic Clinical Factors of Anti-Gamma-Aminobutyric Acid-B Receptor (Gabab-R) Encephalitis in Turkiye: A Multicenter Study

    Ssrn, 2025

    DOI 10.2139/ssrn.5063432 Source: ORCID

  22. Clinical characteristics and prognostic clinical factors of anti-gamma-aminobutyric acid-B receptor (GABAB-R) encephalitis in Türkiye: a multicenter study

    Neurological Research, 2025

    DOI 10.1080/01616412.2025.2495932 PMID 40314255 1 citation (Europe PMC) Open-access full textSource: ORCID

  23. Evaluating the Impact of Heroin Abuse on Cerebral Bioelectrical Activity in Adolescents: A Quantitative Electroencephalography Study

    Neurological Sciences and Neurophysiology, 2025

    DOI 10.4103/nsn.nsn_41_25 Open-access full textSource: ORCID

  24. First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

    Neurotherapeutics, 2025

    DOI 10.1016/j.neurot.2025.e00552 PMID 39965993 5 citations (Europe PMC) Open-access full textSource: ORCID

  25. Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

    Npj Digital Medicine, 2025

    DOI 10.1038/s41746-025-01788-8 PMID 40707601 3 citations (Europe PMC) Open-access full textSource: ORCID

  26. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study

    Journal of Neurology Neurosurgery and Psychiatry, 2025

    DOI 10.1136/jnnp-2024-334090 PMID 39231582 8 citations (Europe PMC) Open-access full textSource: ORCID

  27. Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

    Therapeutic Advances in Neurological Disorders, 2025

    DOI 10.1177/17562864251399595 PMID 41466847 2 citations (Europe PMC) Open-access full textSource: ORCID

  28. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, 2025

    DOI 10.1001/jamaneurol.2025.0495 PMID 40227706 44 citations (Europe PMC) Open-access full textSource: ORCID

  29. Vaccination strategies in multiple sclerosis patients with Delphi methodology: A Turkish consensus

    Neurology Asia, 2025

    DOI 10.54029/2025eme Open-access full textSource: ORCID

  30. Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

    Multiple Sclerosis Journal, 2025

    DOI 10.1177/13524585251349125 PMID 40621862 1 citation (Europe PMC) Open-access full textSource: ORCID

  31. Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability

    JAMA Network Open, 2025

    DOI 10.1001/jamanetworkopen.2025.31581 PMID 40952740 7 citations (OpenAlex) Open-access full textSource: OpenAlex

  32. ECTRIMS 2025 Paper Poster Session 1 and 2

    Multiple Sclerosis Journal, 2025

    DOI 10.1177/13524585251358344 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  33. AB-290. Effectiveness of intermittent theta burst stimulation as an adjunct to constraint-induced movement therapy in patients with stroke to enhance upper extremity recovery: A randomized controlled study

    Clinical Neurophysiology, 2025

    DOI 10.1016/j.clinph.2025.02.098 Source: OpenAlex

  34. Electrodiagnostic methods to verify Guillain‐Barré syndrome subtypes in Istanbul: A prospective multicenter study

    Journal of the Peripheral Nervous System, 2024

    DOI 10.1111/jns.12612 PMID 38291679 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  35. Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis

    Biomedicines, 2024

    DOI 10.3390/biomedicines13010040 PMID 39857624 3 citations (Europe PMC) Open-access full textSource: ORCID

  36. Development, Validity and Reliability of the “Multiple Sclerosis Stigma Scale”

    Multiple Sclerosis and Related Disorders, 2024

    DOI 10.1016/j.msard.2024.105945 PMID 39461168 Source: ORCID

  37. The relationship between optic nerve sheath diameter and demographic and clinical findings in patients diagnosed with clinically isolated syndrome

    Turkish Journal of Clinics and Laboratory, 2024

    DOI 10.18663/tjcl.1549222 Open-access full textSource: ORCID

  38. Arm Swing Movements during Walking as an Early Predictor of Multiple Sclerosis Progression

    Applied Sciences, 2024

    DOI 10.3390/app14156605 Open-access full textSource: ORCID

  39. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

    Journal of Neurology, 2024

    DOI 10.1007/s00415-024-12518-7 PMID 38935148 9 citations (Europe PMC) Open-access full textSource: ORCID

  40. A multicenter multinational study to evaluate different aspects of the relationship between MS and pregnancy

    Multiple Sclerosis and Related Disorders, 2024

    DOI 10.1016/j.msard.2024.105811 PMID 39305566 Source: ORCID

  41. Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein

    Balkan Medical Journal, 2024

    DOI 10.4274/balkanmedj.galenos.2024.2024-1-97 PMID 38828767 2 citations (Europe PMC) Open-access full textSource: ORCID

  42. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

    Journal of Medical Economics, 2024

    DOI 10.1080/13696998.2023.2293379 PMID 38085684 6 citations (Europe PMC) Open-access full textSource: ORCID

  43. Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

    Neurology Neuroimmunology and Neuroinflammation, 2024

    DOI 10.1212/nxi.0000000000200328 PMID 39442037 14 citations (Europe PMC) Open-access full textSource: ORCID

  44. Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes

    Clinical and Experimental Immunology, 2024

    DOI 10.1093/cei/uxad103 PMID 37638717 4 citations (Europe PMC) Open-access full textSource: ORCID

  45. Effectiveness of Intermittent Theta Burst Stimulation to Enhance Upper Extremity Recovery After Stroke: A Pilot Study

    Archives of Physical Medicine and Rehabilitation, 2024

    DOI 10.1016/j.apmr.2024.05.025 PMID 38862033 1 citation (Europe PMC) Source: ORCID

  46. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

    Multiple Sclerosis Journal, 2024

    DOI 10.1177/13524585241267211 PMID 39087208 19 citations (Europe PMC) Open-access full textSource: ORCID

  47. Efficacy of novel haemogram parameters in the evaluation of inflammation in acute ischemic stroke

    Neurology Asia, 2024

    DOI 10.54029/2024yxm 1 citation (OpenAlex) Open-access full textSource: ORCID

  48. Hereditary polyneuropathy with conduction block associated with SORD mutation in three siblings

    Acta Neurologica Belgica, 2024

    DOI 10.1007/s13760-023-02320-z PMID 37418112 2 citations (Europe PMC) Source: ORCID

  49. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    Plos Digital Health, 2024

    DOI 10.1371/journal.pdig.0000533 PMID 39052668 10 citations (Europe PMC) Open-access full textSource: ORCID

  50. Priming constraint-induced movement therapy with intermittent theta burst stimulation to enhance upper extremity recovery in patients with stroke: protocol for a randomized controlled study

    Acta Neurologica Belgica, 2024

    DOI 10.1007/s13760-024-02472-6 PMID 38329642 1 citation (Europe PMC) Source: ORCID